title: Abnormal analyte preeclampsia: do the second-trimester maternal serum analytes help differentiate preeclampsia subtypes?
abstract: OBJECTIVE
  To determine if serum screen analytes identify preeclamptic patients at risk for small-for-gestational age newborns, maternal laboratory abnormalities and preterm delivery (<37 weeks gestation).
  
  
  METHODS
  Using a retrospective cohort of 102 preeclamptic patients, associations between serum screen analytes and newborn birth-weight percentile, gestational age (GA) at delivery and maternal pre-delivery laboratory abnormalities were evaluated using correlation coefficients and local polynomial regression.
  
  
  RESULTS
  Inhibin-A and maternal serum alpha fetoprotein were inversely correlated with newborn birth-weight percentile (-0.27, P=0.006; -0.35, P=0.00004) and delivery GA (r=-0.42, P<0.0001; r=-0.26, P=0.008) and positively correlated with pre-delivery aspartate aminotransferase (r=0.22, P=0.03; r=0.21, P=0.04) and lactate dehydrogenase (r=0.33, P=0.0007; r=0.29, P=0.004). A positive correlation was noted between both second-trimester beta human chorionic gonadotropin and estriol and maternal pre-delivery creatinine (0.28, P=0.004; 0.4, P<0.0001, respectively). Hundred percent of patients with ≥ 2 abnormal analytes delivered before 37 weeks gestation.
  
  
  CONCLUSIONS
  Preeclamptic patients with abnormal serum screen analytes are more likely to have small-for-gestational age newborns, deliver preterm and have pre-delivery laboratory abnormalities.
authors.affiliation: Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Critchfield
authors.forename: J K
authors.initials: JK
authors.lastname: Paulus
authors.forename: R
authors.initials: R
authors.lastname: Farez
authors.forename: A C
authors.initials: AC
authors.lastname: Urato
mesh_terms: D000328:Adult; D001724:Birth Weight; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D004964:Estriol / Q000097:blood; D005260:Female; D005865:Gestational Age; D017359:HELLP Syndrome / Q000097:blood; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age / Q000097:blood; D007265:Inhibins / Q000097:blood; D062145:Maternal Serum Screening Tests; D011225:Pre-Eclampsia / Q000097:blood* / Q000145:classification / Q000175:diagnosis; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000097:blood*; D011262:Pregnancy Trimester, Second; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis; D047928:Premature Birth / Q000097:blood; D012189:Retrospective Studies; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D018997:Chorionic Gonadotropin, beta Subunit, Human; D011257:Pregnancy Proteins; D000509:alpha-Fetoproteins; C422362:inhibin A; D007265:Inhibins; D011266:Pregnancy-Associated Plasma Protein-A; D004964:Estriol